Ardena annouced that it is entering into a partnership with Citryll, a private pharmaceutical company focusing on the development and commercialization of antibody therapeutics that target innate immunity. The team around Melloney Dröge is pleased to support Citryll in the clinical development of CIT-013, antagonist of Neutrophil Extracellular Traps (NET) biology and associated pathologies. The service package comprises full bioanalytical support from the development of PK, immunogenicity, PD and safety assays, right up to the validation of the methods and subsequent bioanalytical clinical sample analysis. Ardena will eagerly follow the course of the clinical study.